Current Topics in Oncology

Download All
Experts discuss key topics in contemporary cancer treatment in this podcast series that includes downloadable summary slidesets.
Nilofer S. Azad, MD
person default
Jean Yves Blay, MD, PhD
Chiara Cremolini, MD, PhD
Karim Fizazi, MD, PhD
Joleen Hubbard, MD
Robin L. Jones, BSc, MBBS, MRCP, MD(Res)
Josep M. Llovet, MD
person default
Teresa Macarulla, MD
John L. Marshall, MD
Alicia K. Morgans, MD, MPH
Chris Parker, MD
Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA
Kanwal Raghav, MD
person default
Rachel Riechelmann, MD, PhD
Bertrand Tombal, MD, PhD

TKIs in Solid Tumors

In this podcast episode, Jean-Yves Blay, MD, PhD, and Robin L. Jones, BSc, MBBS, MRCP, MD(Res), discuss key data on using TKIs as monotherapy and in combination with chemotherapy or immune checkpoint inhibitors for treatment of soft tissue sarcoma and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 2, 2021

Download this summary slideset to accompany a podcast featuring expert discussion on key clinical trial data on leveraging TKIs as single agents or in combination with cytotoxics or immune checkpoint inhibitors for treatment of soft tissue sarcomas and osteosarcoma.

person default Jean Yves Blay, MD, PhD Robin L. Jones, BSc, MBBS, MRCP, MD(Res) Released: November 3, 2021

In this podcast episode, experts Josep M. Llovet, MD, PhD, and Univ. Prof. Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

Summary slides for a podcast where Josep M. Llovet, MD, PhD, and Markus Peck-Radosavljevic, MD, MBA, discuss the evolving role of tyrosine kinase inhibitors in the first-line treatment of patients with advanced hepatocellular carcinoma.

Josep M. Llovet, MD Univ. Prof. Dr. Markus Peck-Radosavljevic, MD, MBA Released: December 14, 2021

A Focus on VEGF TKIs

Listen to Joleen Hubbard, MD, and John L. Marshall, MD, discuss the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and key adverse events.

Joleen Hubbard, MD John L. Marshall, MD Released: April 29, 2021

Download this slideset for key insights from our podcast featuring an expert discussion of the use of key later-line treatment options for patients with mCRC, including optimal treatment sequencing and dosing and how adverse events influence therapy decisions.

Joleen Hubbard, MD John L. Marshall, MD Released: April 29, 2021

Listen to Kanwal Raghav, MD, and Rachel Riechelmann, MD, PhD, as they provide their clinical insights into dosing of key later-line treatment options for patients with mCRC.

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Download this slideset for key insights from a podcast featuring an expert discussion of dosing of key later-line treatment options for patients with mCRC.

Kanwal Raghav, MD person default Rachel Riechelmann, MD, PhD Released: October 21, 2021

Listen to Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, as they discuss the clinical data that inform how they select later-line treatment for patients with mCRC.

Chiara Cremolini, MD, PhD person default Teresa Macarulla, MD Released: December 17, 2021

Download this slideset for key insights from a podcast featuring an expert discussion of clinical data informing the selection of later-line treatment for patients with mCRC.

Chiara Cremolini, MD, PhD person default Teresa Macarulla, MD Released: December 20, 2021

Listen to Nilofer S. Azad, MD, and Kanwal Raghav, MD, as they discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC.

Nilofer S. Azad, MD Kanwal Raghav, MD Released: April 6, 2022

Download this slideset for key insights from a podcast featuring an expert discussion of current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC.

Nilofer S. Azad, MD Kanwal Raghav, MD Released: April 6, 2022

Current Topics in Oncology: A Focus on Prostate Cancer

In this podcast episode, listen to Chris Parker, MD, and Bertrand Tombal, MD, PhD, as they discuss clinical implications of the latest data from ASCO 2021 on using radium-223, PSMA lutetium, and bone health approaches for the treatment and management of patients with metastatic castration-resistant prostate cancer.

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

Download this Podcast Pearls slideset based on the content from a CCO podcast covering recent new developments in the treatment of patients with metastatic castration-resistant prostate cancer.

Chris Parker, MD Bertrand Tombal, MD, PhD Released: July 20, 2021

In this podcast episode, listen to Karim Fizazi, MD, PhD, and Alicia K. Morgans, MD, MPH, as they discuss clinical implications of the latest data from ASCO 2021 on using androgen receptor–directed therapy for the treatment and management of patients with nonmetastatic castration-resistant prostate cancer.

Karim Fizazi, MD, PhD Alicia K. Morgans, MD, MPH Released: July 30, 2021

Download this Podcast Pearls slideset based on the content from a CCO podcast covering the latest data on next-generation androgen receptor inhibitors for treatment of patients with nonmetastatic castration-resistant prostate cancer.

Karim Fizazi, MD, PhD Alicia K. Morgans, MD, MPH Released: July 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings